Myriad Genetics (MYGN) Depreciation & Amortization (CF) (2009 - 2026)

Myriad Genetics (MYGN) has reported Depreciation & Amortization (CF) for 18 consecutive years, with $12.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 13.19% year-over-year to $12.5 million; the TTM figure through Mar 2026 stood at $51.8 million (down 13.52% YoY), while the FY2025 annual figure was $53.7 million, down 12.25% from the prior year.
• Depreciation & Amortization (CF) retreated to $12.5 million in Q1 2026 per MYGN's latest filing, from $12.6 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $19.4 million in Q1 2023 and bottomed at $12.5 million in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $14.2 million across 5 years, with a median of $14.1 million in 2023.
• Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) declined 29.35% — and 2023, when it jumped 49.23%.
• Myriad Genetics' Depreciation & Amortization (CF) stood at $13.7 million in 2022, then rose by 10.22% to $15.1 million in 2023, then dropped by 1.99% to $14.8 million in 2024, then retreated by 14.86% to $12.6 million in 2025, then slipped by 0.79% to $12.5 million in 2026.
• Business Quant data shows MYGN's Depreciation & Amortization (CF) at $12.5 million in Q1 2026, $12.6 million in Q4 2025, and $12.6 million in Q3 2025.